Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
21 mai 2024 17h15 HE
|
Alvotech
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period...
Alvotech birtir uppgjör fyrir fyrsta ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
21 mai 2024 17h14 HE
|
Alvotech
Heildartekjur á fyrsta ársfjórðungi 2024 jukust í 37 milljónir dollara, úr 16 milljónum dollara á sama tímabili í fyrraFramlegð á fyrsta fjórðungi 2024 var 17 milljónir dala, sem er 40 milljóna...
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
21 mai 2024 17h14 HE
|
Alvotech
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last yearGross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last...
Alvotech gengur til samstarfs við Dr. Reddy‘s um markaðssetningu AVT03, fyrirhugaðrar hliðstæðu við Prolia og Xgeva, í Bandaríkjunum og Evrópu
21 mai 2024 08h01 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gert samstarfssamning við Dr. Reddy’s Laboratories SA, dótturfyrirtæki Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) um sölu- og...
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
21 mai 2024 08h01 HE
|
Alvotech
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)Alvotech will be responsible for development and...
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
21 mai 2024 08h00 HE
|
Alvotech
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and...
Alvotech og Teva Pharmaceuticals hefja sölu á líftæknilyfjahliðstæðunni Simlandi í Bandaríkjunum
20 mai 2024 20h25 HE
|
Alvotech
Simlandi er fyrsta líftæknilyfjahliðstæðan í háum styrk með útskiptanleika við Humira á markaði í Bandaríkjunum Alvotech (NASDAQ: ALVO) og samstarfsaðili þess Teva Pharmaceuticals Ltd. tilkynntu í...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
20 mai 2024 20h25 HE
|
Alvotech
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
20 mai 2024 20h25 HE
|
Alvotech
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S....
Aðalfundur Alvotech S.A. boðaður 7. júní 2024
15 mai 2024 09h30 HE
|
Alvotech
Aðalfundur Alvotech S.A. verður haldinn föstudaginn 7. júní 2024, kl. 09.00 CEST á skrifstofu Arendt & Medernach S.A að 41A Avenue John F. Kennedy, L-1855 Lúxemborg. Drög af dagskrá fundarins er...